New York recalls

A New Life Herbs is recalling its Organic Ginger Root Herbal Supplement because the product makes unapproved drug claims on its label and is missing required Supplement Facts labeling. The product was sold in 50-capsule plastic bags in multiple states.

A New Life Herbs is recalling its Mullein flower alcohol tincture ear drops because the product makes unapproved claims about treating pain and infection, and the bottle lacks required supplement labeling. The FDA found 22 bottles (lot T553MF, expiring 12/28) distributed across multiple states.

A New Life Herbs Chaga Mushroom herbal supplement is being recalled because the label makes unapproved health claims (such as anti-cancer properties) and is missing required supplement information. The product does not meet FDA labeling standards for dietary supplements.

A New Life Herbs is recalling its Boswellia Herbal Supplement (2 oz. glass dropper bottle) because the product makes unapproved medical claims on its label and is missing required Supplement Facts labeling. The product was distributed in multiple states.

A New Life Herbs Baby Soothe herbal supplement is being recalled because it makes disease claims on the label without FDA approval and is missing required supplement facts information. The product was distributed in Alabama, Arizona, California, Georgia, Illinois, Indiana, Minnesota, Missouri, Mississippi, North Carolina, New York, and Tennessee.

A New Life Herbs is recalling its Baby Allergy Herbal Supplement because the product makes drug claims on the label that are not approved by the FDA, and it is missing required Supplement Facts labeling. The product contains echinacea, Oregon grape root, dandelion, burdock root, fenugreek, and ginger root in vegetable glycerin, sold in a 2 oz. glass dropper bottle.

A New Life Herbs is recalling its Anti-virus Herbal Supplement tincture because the product label makes drug claims that are not approved by the FDA and is missing required supplement nutrition information. The product was sold in 2 oz. glass dropper bottles in several states.

Choceur Cookie Butter Holiday Bark sold at Aldi contains pecan that is not listed on the label. People with pecan allergies could have a serious reaction if they eat this product. The recall affects specific lot numbers with best-by dates through June 2026.

Choceur Pecan Cranberry & Cinnamon Holiday Bark contains wheat that is not listed on the label. People with wheat allergies or celiac disease could have a serious reaction if they eat this product. The affected bags were sold at Aldi stores nationwide.

Wegmans Deluxe Mixed Nuts in two sizes may be contaminated with Salmonella, a bacteria that can cause serious illness. The affected products were distributed to stores in Pennsylvania and New York. No illnesses have been reported yet.

Wegmans grated Pecorino Romano cheese (Locatelli brand, item #270010) sold in clear plastic tubs may be contaminated with Listeria monocytogenes, a bacteria that can cause serious illness. The affected cheese was sold between November 29 and December 7, 2025, in Wegmans stores across the Northeast and Mid-Atlantic regions.

Some packages of Ritz Peanut Butter Cracker Sandwiches (27.6 oz, 20-count boxes) were mislabeled and may contain peanuts that are not declared on the package. This poses a serious risk to people with peanut allergies. The affected product was distributed in Alabama, Georgia, New Jersey, Pennsylvania, New York, Oklahoma, Arkansas, and Missouri.

Grandma Belle's Tomato Basil Soup (17 oz glass jars) may contain milk that is not listed on the label. The product was distributed across 14 states. No illnesses have been reported, but people with milk allergies or sensitivity could have a serious reaction if they consume it.

Merck has recalled specific lots of Noxafil Powdermix, a prescription antifungal medication, because some packets may contain metal particles. This affects 845 kits distributed nationwide. No injuries have been reported.

Merck has recalled a limited lot of Emend (aprepitant) 125 mg oral suspension due to the potential presence of metal particles in the product. This affects 3 single-dose kits with lot number Z014503 and expiration date 11/15/2027 distributed nationwide.

Abbott Laboratories is recalling certain Alinity ci-series System Control Modules with software version 3.6.1 or lower due to a performance issue that could produce inaccurate lab test results. The issue affects multiple analytes and was discovered during Abbott's internal testing.

Cepheid's Xpert BCR-ABL Ultra diagnostic test kits may produce inaccurate results when testing blood samples with very high white blood cell counts (above 30,000 cells). This affects certain lot numbers distributed across the US and internationally. No injuries have been reported.

Cepheid's Xpert BCR-ABL Ultra diagnostic test kits may give inaccurate results when testing blood samples with very high white blood cell counts (over 30,000 cells). This affects specific lot numbers distributed across the US and internationally. No injuries have been reported.

Medtronic MiniMed InPen App users on Android (versions 7.5.0, 7.5.1, and 8.0.0) may lose insulin reminders if they uninstall and reinstall the app. The notification settings screen doesn't appear during setup, preventing notifications from overriding your phone's mute or Do Not Disturb mode. This could delay insulin therapy.

Smith & Nephew is recalling certain BIOSURE HA Screws (6mm x 20mm bone fixation screws) due to a labeling error on affected units. The screws themselves are safe, but the packaging labels on a small number of units contain incorrect information. No injuries have been reported.

Myofunctional Research Company USA distributed Myosa for Kids mouthguards in the U.S. without FDA approval. The company mistakenly sold approximately 436 units of these devices, which are designed for children ages 3–15 to help with breathing and myofunctional disorders. No injuries have been reported.

DSAART LLC distributed calf implants that did not meet FDA requirements. The products were sold without required FDA premarket approval or clearance, and some deviated from manufacturing specifications. Approximately 35 implants were distributed across multiple U.S. states.

DSAART LLC distributed AART Pectoral Implants that were manufactured differently than approved and were sold without required FDA clearance. The implants do not meet established safety and quality standards. Affected models were distributed across multiple U.S. states.

DSAART LLC distributed AART Malar Implants (model 401-202-5 and 401-202-6, lot numbers 24-01-014 and 24-01-015) without obtaining required FDA premarket approval and with deviations from established manufacturing specifications. Two implants were affected and distributed across multiple U.S. states.

DSAART LLC distributed AART Chin Implants that were manufactured with deviations from established specifications and without obtaining required FDA premarket approvals or clearances. The affected implants were distributed across multiple U.S. states.

DSAART LLC distributed gluteal implants without FDA approval and in ways that deviated from approved specifications. The FDA has recalled 118 implants across multiple models and lot numbers distributed in 28 U.S. states and territories. No injuries have been reported.

DSAART LLC distributed AART Silicone Carving Implants without obtaining required FDA premarket approval or clearance, and some products deviated from established manufacturing specifications. These implants are used in augmentation and reconstructive surgery. The FDA has issued a Class II recall affecting 369 implants distributed across multiple U.S. states.

Copan Italia's DTT (dithiothreitol) liquid reagent, used to prepare respiratory specimens in laboratories, may not work properly. The reagent is supplied in 1ml PET tubes with capture caps. There have been no reported injuries, but the functionality cannot be guaranteed for specimen fluidification.

Copan Italia's DTT (dithiothreitol) reagent tubes used with the WASP microbiology system may not reliably liquefy respiratory specimens as intended. This could affect the quality of lab test results. The issue affects approximately 122,850 units distributed across multiple US states.

Intelerad InteleShare medical imaging software versions 3.24.3 through 3.25.2 contain a bug that can produce inaccurate measurement values when certain viewing features are used together. This could lead to incorrect measurements on medical images, potentially affecting diagnosis and treatment planning.